Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy

被引:28
|
作者
Takekuma, Munetaka [1 ]
Kasamatsu, Yuka [1 ]
Kado, Nobuhiro [1 ]
Kuji, Shiho [1 ]
Tanaka, Aki [1 ]
Takahashi, Nobutaka [1 ]
Abe, Masakazu [1 ]
Hirashima, Yasuyuki [1 ]
机构
[1] Shizuoka Canc Ctr, Div Gynecol, 1007 Shimonagakubo, Shizuoka 4118777, Japan
关键词
Cervical cancer; Postoperative adjuvant therapy; Chemotherapy; CCRT; RADIATION-THERAPY; PELVIC RADIATION; LYMPH-NODES; CARCINOMA; RADIOTHERAPY; CISPLATIN; FLUOROURACIL;
D O I
10.1007/s10147-016-0955-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aims of this study were to evaluate the efficacy and toxicity of chemotherapy (CT) compared with concurrent chemoradiotherapy (CCRT) after radical hysterectomy and lymphadenectomy in high-risk patients with early-stage cervical cancer and to evaluate whether the radicality of the lymphadenectomy would affect the outcome and toxicity of postoperative adjuvant therapy. The cases of all patients (n = 393) with FIGO IB1-IIB cervical cancer who were treated by radical surgery at Shizuoka Cancer Center between January 2002 and December 2013 were reviewed. Of these, 111 patients met the inclusion criteria for this retrospective study: (1) high risk for occurrence due to pathologically confirmed parametrial invasion and/or pelvic lymph node metastasis; (2) postoperative treatment with adjuvant CT or CCRT. The clinical data of these patients were reviewed. Of the 111 patients, 37 and 74 patients underwent CT and CCRT, respectively. The 4-year progression-free survival rate [PFS; 71.7 (CT) vs. 68.3 % (CCRT)] and overall survival rate [76.0 (CT) vs. 82.7 % (CCRT)] did not differ significantly between the two groups. The CT group contained significantly more patients with severe neutropenia than the CCRT group (66.7 vs. 23.0 %, respectively; p < 0.001), and the CCRT group contained significantly more patients with diarrhea than the CT group (10.8 vs. 0 %, respectively; p = 0.04). The patients who had a parts per thousand yen40 lymph nodes dissected (a parts per thousand yen40 group) had higher PFS than the patients who had < 40 lymph nodes dissected (< 40 group) (73.2 vs. 64.2 %, respectively), although the difference was not significant. In the CT group, there was no significant association between the number of dissected lymph nodes and severe toxicities. However, in the CCRT group, significantly more vomiting (p = 0.046) and edema (p = 0.046) occurred in the a parts per thousand yen40 group than in the < 40 group. Chemotherapy after surgery for high-risk patients had similar efficacy and a different toxicity profile compared with CCRT, and a more radical surgical procedure would improve the survival outcome. However, CCRT was associated with worse toxicity than CT. We advocate a prospective randomized study to compare CT with CCRT for patients with high-risk factors for recurrence.
引用
收藏
页码:741 / 747
页数:7
相关论文
共 50 条
  • [1] Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy
    Munetaka Takekuma
    Yuka Kasamatsu
    Nobuhiro Kado
    Shiho Kuji
    Aki Tanaka
    Nobutaka Takahashi
    Masakazu Abe
    Yasuyuki Hirashima
    [J]. International Journal of Clinical Oncology, 2016, 21 : 741 - 747
  • [2] Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy
    Hosaka, Masayoshi
    Watari, Hidemichi
    Takeda, Mahito
    Moriwaki, Masashi
    Hara, Yoko
    Todo, Yukiharu
    Ebina, Yasuhiko
    Sakuragi, Noriaki
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2008, 34 (04) : 552 - 556
  • [3] Risk factors of recurrence after adjuvant concurrent chemoradiotherapy following radical hysterectomy in high-risk patients with cervical cancer
    Chung, H.
    Kim, J.
    Park, N.
    Song, Y.
    Kang, S.
    Lee, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors
    Kim, Yong Bae
    Cho, Jae Ho
    Keum, Ki Chang
    Lee, Chang Geol
    Seong, Jinsil
    Suh, Chang Ok
    Kim, Gwi Eon
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 104 (01) : 58 - 63
  • [5] Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy
    Sang-Won Kim
    Mison Chun
    Hee-Sug Ryu
    Suk-Joon Chang
    Tae Wook Kong
    Young-Taek Oh
    Seung Hee Kang
    [J]. BMC Cancer, 17
  • [6] Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy
    Kim, Sang-Won
    Chun, Mison
    Ryu, Hee-Sug
    Chang, Suk-Joon
    Kong, Tae Wook
    Oh, Young-Taek
    Kang, Seung Hee
    [J]. BMC CANCER, 2017, 17
  • [7] Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy
    Kim, Hakyoung
    Cho, Won Kyung
    Kim, Yeon Joo
    Kim, Young Seok
    Park, Won
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 423 - 428
  • [8] Is concurrent chemoradiation a choice for high-risk cervical cancer patients after radical hysterectomy?
    Wang, Peng-Hui
    Cheng, Ming-Huei
    Yuan, Chiou-Chung
    Yen, Ming-Shyen
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (01) : 102 - 103
  • [9] Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): A randomized phase III trial
    Curtin, JP
    Hoskins, WJ
    Venkatraman, ES
    Almadrones, L
    Podratz, KC
    Long, H
    Teneriello, M
    Averette, H
    Sevin, BU
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 61 (01) : 3 - 10
  • [10] A PILOT-STUDY OF ADJUVANT THERAPY IN PATIENTS WITH CERVICAL-CANCER AT HIGH-RISK OF RECURRENCE AFTER RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY
    WERTHEIM, MS
    HAKES, TB
    DAGHESTANI, AN
    NORI, D
    SMITH, DH
    LEWIS, JL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (07) : 912 - 916